ACT Genomics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 300

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $20M

ACT Genomics General Information

Description

Provider of cancer molecular information services designed to rewrite the existing model of diagnostic, treatment, and monitoring. The company's cancer molecular information services implement next-generation sequencing and multiplex molecular testing, coupled with bioinformatics tools, curated proprietary databases and data visualization technologies, enabling oncologists to address the key challenges in cancer treatments.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Clinics/Outpatient Services
Other Industries
Biotechnology
Parent Company
Corporate Office
  • 3F., No.345, Xinhu 2nd Rd.
  • Neihu District
  • Taipei, 114
  • Taiwan
+886 02 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ACT Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 30-Dec-2022 $20M 0000 0000 Completed Profitable
4. Later Stage VC (Series D) 01-Jan-2021 0000 Completed Profitable
3. Early Stage VC 26-Sep-2018 000.00 0000 Completed Startup
2. Early Stage VC (Series B) 01-May-2016 $12.5M $20.5M Completed Startup
1. Early Stage VC (Series A) 13-Feb-2015 $8M $8M Completed Startup
To view ACT Genomics’s complete valuation and funding history, request access »

ACT Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Provider of cancer molecular information services designed to rewrite the existing model of diagnostic, treatment, and m
Clinics/Outpatient Services
Taipei, Taiwan
300 As of 2022
0000
0000 0000-00-00
000000&0 0000

000000

mco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in re
0000000000 00000000
Cambridge, United Kingdom
00 As of 0000

00000

n ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
0000000000000
Nashik, India
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ACT Genomics Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oncologica Corporation Cambridge, United Kingdom 00
Datar Cancer Genetics Formerly VC-backed Nashik, India 000 00000 00000000000 00000
MedGenome Private Equity-Backed Foster City, CA 0000 00000 00000000000 00000
Foundation Medicine Formerly VC-backed Cambridge, MA 0000 00000 00000000000
Gene By Gene Formerly Accelerator/Incubator backed Houston, TX 00 000000&0
You’re viewing 5 of 22 competitors. Get the full list »

ACT Genomics Patents

ACT Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190385701-A1 Method and system for sequence alignment and variant calling Active 29-Dec-2017 000000000 0
US-10854317-B2 Method and system for sequence alignment and variant calling Active 29-Dec-2017 000000000 0

ACT Genomics Executive Team (7)

Name Title Board Seat Contact Info
Hua Chien Chen Ph.D Co-Founder & Chief Executive Officer
Yaoqiang Chen Chief Financial Officer
Liheng Rong Chief Operating Officer
Shu Jen Chen Ph.D Co-Founder & Chief Scientific Officer
Peter Wong Ph.D Interim Chief Information Officer
You’re viewing 5 of 7 executive team members. Get the full list »

ACT Genomics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ACT Genomics Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aflac Ventures Corporate Venture Capital Minority 000 0000 000000 0
CDIB Capital International PE/Buyout Minority 000 0000 000000 0
CLSA Capital Partners PE/Buyout Minority 000 0000 000000 0
Drive Catalyst Corporate Venture Capital Minority 000 0000 000000 0
Eminent Venture Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

ACT Genomics Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Joint Venture (Cerba Research / ACT Genomics) 24-Aug-2021 00000 0000 Laboratory Services (Healthcare) 000 00000
MC Diagnostics 06-Jul-2021 0000000000 Biotechnology 000 00000
ACTmed 01-Apr-2017 Joint Venture Drug Discovery
To view ACT Genomics’s complete investments and acquisitions history, request access »

ACT Genomics Subsidiaries (2)

Company Name Industry Location Founded
Sanomics Biotechnology Hong Kong, Hong Kong 2015
MC Diagnostics Biotechnology Bromborough, United Kingdom 0000
To view ACT Genomics’s complete subsidiaries history, request access »

ACT Genomics FAQs

  • When was ACT Genomics founded?

    ACT Genomics was founded in 2013.

  • Who is the founder of ACT Genomics?

    Hua Chien Chen Ph.D and Shu Jen Chen Ph.D are the founders of ACT Genomics.

  • Who is the CEO of ACT Genomics?

    Hua Chien Chen Ph.D is the CEO of ACT Genomics.

  • Where is ACT Genomics headquartered?

    ACT Genomics is headquartered in Taipei, Taiwan.

  • What is the size of ACT Genomics?

    ACT Genomics has 300 total employees.

  • What industry is ACT Genomics in?

    ACT Genomics’s primary industry is Clinics/Outpatient Services.

  • Is ACT Genomics a private or public company?

    ACT Genomics is a Private company.

  • What is the current valuation of ACT Genomics?

    The current valuation of ACT Genomics is 0000.

  • What is ACT Genomics’s current revenue?

    The current revenue for ACT Genomics is 000000.

  • How much funding has ACT Genomics raised over time?

    ACT Genomics has raised $50M.

  • Who are ACT Genomics’s investors?

    Aflac Ventures, CDIB Capital International, CLSA Capital Partners, Drive Catalyst, and Eminent Venture Capital are 5 of 13 investors who have invested in ACT Genomics.

  • Who are ACT Genomics’s competitors?

    Oncologica, Datar Cancer Genetics, MedGenome, Foundation Medicine, and Gene By Gene are some of the 22 competitors of ACT Genomics.

  • When was ACT Genomics acquired?

    ACT Genomics was acquired on 30-Dec-2022.

  • Who acquired ACT Genomics?

    ACT Genomics was acquired by Prenetics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »